Literature DB >> 17215336

Protection against porcine reproductive and respiratory syndrome virus (PRRSV) infection through passive transfer of PRRSV-neutralizing antibodies is dose dependent.

O J Lopez1, M F Oliveira, E Alvarez Garcia, B J Kwon, A Doster, F A Osorio.   

Abstract

Previous work in our laboratory demonstrated that passive transfer of porcine reproductive and respiratory syndrome virus (PRRSV)-neutralizing antibodies (NA) protected pregnant sows against reproductive failure and conferred sterilizing immunity in sows and offspring. We report here on the dose requirement for protection by passive transfer with NA in young weaned pigs. The presence of a 1:8 titer of PRRSV-NA in serum consistently protected pigs against viremia. Nevertheless, their lungs, tonsils, buffy coat cells, and peripheral lymph nodes contained replicating PRRSV similar to the infected control group. Likewise, these animals excreted infectious virus to sentinels similar to the infectivity control animals. In an attempt to reach complete protective immunity equivalent to that previously observed in sows, the pigs were transferred with a higher titer of PRRSV-NA (1:32), and even then apparent sterilizing immunity was attained in only 50% of the animals. In conclusion, the presence of anti-PRRSV-NA in serum with a titer of 1:8 is enough to block viremia but not peripheral tissue seeding and transmission to contact animals. While a relatively low level of NA in blood is capable of conferring sterilizing immunity against PRRSV in sows, the amount of NA necessary to obtain full protection of a young weaned pig would be significantly higher, suggesting that differences exist in the PRRSV pathogenesis between both age groups. In addition, the titer of NA could be a helpful parameter of protection in the assessment of PRRSV vaccines.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17215336      PMCID: PMC1828847          DOI: 10.1128/CVI.00304-06

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  17 in total

Review 1.  Proinflammatory cytokines and viral respiratory disease in pigs.

Authors:  K van Reeth; H Nauwynck
Journal:  Vet Res       Date:  2000 Mar-Apr       Impact factor: 3.683

2.  Passive transfer of virus-specific antibodies confers protection against reproductive failure induced by a virulent strain of porcine reproductive and respiratory syndrome virus and establishes sterilizing immunity.

Authors:  F A Osorio; J A Galeota; E Nelson; B Brodersen; A Doster; R Wills; F Zuckermann; W W Laegreid
Journal:  Virology       Date:  2002-10-10       Impact factor: 3.616

3.  A 10-kDa structural protein of porcine reproductive and respiratory syndrome virus encoded by ORF2b.

Authors:  W H Wu; Y Fang; R Farwell; M Steffen-Bien; R R Rowland; J Christopher-Hennings; E A Nelson
Journal:  Virology       Date:  2001-08-15       Impact factor: 3.616

4.  Porcine reproductive and respiratory syndrome virus: description of persistence in individual pigs upon experimental infection.

Authors:  R Allende; W W Laegreid; G F Kutish; J A Galeota; R W Wills; F A Osorio
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

5.  Identification of neutralizing and nonneutralizing epitopes in the porcine reproductive and respiratory syndrome virus GP5 ectodomain.

Authors:  M Ostrowski; J A Galeota; A M Jar; K B Platt; F A Osorio; O J Lopez
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

6.  Transmission of porcine reproductive and respiratory syndrome virus from persistently infected sows to contact controls.

Authors:  M D Bierk; S A Dee; K D Rossow; S Otake; J E Collins; T W Molitor
Journal:  Can J Vet Res       Date:  2001-10       Impact factor: 1.310

7.  Gradual development of the interferon-gamma response of swine to porcine reproductive and respiratory syndrome virus infection or vaccination.

Authors:  William A Meier; Judy Galeota; Fernando A Osorio; Robert J Husmann; William M Schnitzlein; Federico A Zuckermann
Journal:  Virology       Date:  2003-04-25       Impact factor: 3.616

8.  The level of virus-specific T-cell and macrophage recruitment in porcine reproductive and respiratory syndrome virus infection in pigs is independent of virus load.

Authors:  Zhengguo Xiao; Laura Batista; Scott Dee; Patrick Halbur; Michael P Murtaugh
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

9.  Pathogenesis of porcine reproductive and respiratory syndrome virus infection in gnotobiotic pigs.

Authors:  K D Rossow; J E Collins; S M Goyal; E A Nelson; J Christopher-Hennings; D A Benfield
Journal:  Vet Pathol       Date:  1995-07       Impact factor: 2.221

10.  Mutations in the genome of porcine reproductive and respiratory syndrome virus responsible for the attenuation phenotype.

Authors:  R Allende; G F Kutish; W Laegreid; Z Lu; T L Lewis; D L Rock; J Friesen; J A Galeota; A R Doster; F A Osorio
Journal:  Arch Virol       Date:  2000       Impact factor: 2.574

View more
  74 in total

1.  Porcine reproductive and respiratory syndrome virus neutralizing antibodies provide in vivo cross-protection to PRRSV1 and PRRSV2 viral challenge.

Authors:  Sally R Robinson; Michael C Rahe; Diem K Gray; Kyra V Martins; Michael P Murtaugh
Journal:  Virus Res       Date:  2018-02-03       Impact factor: 3.303

2.  Exosomes Mediate Intercellular Transmission of Porcine Reproductive and Respiratory Syndrome Virus.

Authors:  Ting Wang; Liurong Fang; Fuwei Zhao; Dang Wang; Shaobo Xiao
Journal:  J Virol       Date:  2018-01-30       Impact factor: 5.103

3.  Porcine Reproductive and Respiratory Syndrome Virus Utilizes Nanotubes for Intercellular Spread.

Authors:  Rui Guo; Benjamin B Katz; John M Tomich; Tom Gallagher; Ying Fang
Journal:  J Virol       Date:  2016-04-29       Impact factor: 5.103

4.  Nsp2 and GP5-M of Porcine Reproductive and Respiratory Syndrome Virus Contribute to Targets for Neutralizing Antibodies.

Authors:  Jia Su; Lei Zhou; Bicheng He; Xinhui Zhang; Xinna Ge; Jun Han; Xin Guo; Hanchun Yang
Journal:  Virol Sin       Date:  2019-07-25       Impact factor: 4.327

5.  Immune evasion of porcine reproductive and respiratory syndrome virus through glycan shielding involves both glycoprotein 5 as well as glycoprotein 3.

Authors:  Hiep L X Vu; Byungjoon Kwon; Kyoung-Jin Yoon; William W Laegreid; Asit K Pattnaik; Fernando A Osorio
Journal:  J Virol       Date:  2011-03-16       Impact factor: 5.103

6.  Immunopotentiation of four natural adjuvants co-administered with a highly pathogenic porcine reproductive and respiratory syndrome virus glycoprotein 5 subunit.

Authors:  Jun Peng; Yanmei Yuan; Si Shen; Zhongxiang Niu; Yijun Du; Jiaqiang Wu; Jun Li; Jiang Yu; Tao Wang; Jinbao Wang
Journal:  Virus Genes       Date:  2016-02-08       Impact factor: 2.332

7.  Pathogenesis and antigenic characterization of a new East European subtype 3 porcine reproductive and respiratory syndrome virus isolate.

Authors:  Uladzimir U Karniychuk; Marc Geldhof; Merijn Vanhee; Jan Van Doorsselaere; Tamara A Saveleva; Hans J Nauwynck
Journal:  BMC Vet Res       Date:  2010-06-04       Impact factor: 2.741

8.  A Synthetic Porcine Reproductive and Respiratory Syndrome Virus Strain Confers Unprecedented Levels of Heterologous Protection.

Authors:  Hiep L X Vu; Fangrui Ma; William W Laegreid; Asit K Pattnaik; David Steffen; Alan R Doster; Fernando A Osorio
Journal:  J Virol       Date:  2015-09-23       Impact factor: 5.103

9.  Immune responses in mice vaccinated with virus-like particles composed of the GP5 and M proteins of porcine reproductive and respiratory syndrome virus.

Authors:  Hae-Mi Nam; Kyung-Sil Chae; Young-Jo Song; Nak-Hyung Lee; Joong-Bok Lee; Seung-Yong Park; Chang-Seon Song; Kun-Ho Seo; Sang-Moo Kang; Min-Chul Kim; In-Soo Choi
Journal:  Arch Virol       Date:  2013-02-08       Impact factor: 2.574

10.  Porcine Reproductive and Respiratory Syndrome Virus Promotes SLA-DR-Mediated Antigen Presentation of Nonstructural Proteins To Evoke a Nonneutralizing Antibody Response In Vivo.

Authors:  Chunyan Wu; Bingjun Shi; Di Yang; Kun Zhang; Jie Li; Jie Wang; Hongliang Liu; Qin Zhao; En-Min Zhou; Yuchen Nan
Journal:  J Virol       Date:  2020-10-14       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.